Sunday, January 03, 2010

Shire Tweets To Boost ADHD Sales

Shire plc (SHPGY-$58.70) has been unable to capitalize on its historically dominant position in the attention deficit/hyperactivity disorder (ADHD) realm (33 percent of the branded U.S. marketing pie in 2008) and a three-year co-promotion agreement signed with GlaxoSmithKline (started in May 2009): Vyvanse (lisdexamfetamine dimesylate) sales totaled just $129 million in the third-quarter ending September 2009.

Aiming to improve the recognition and treatment of ADHD in kid and adult populations – and boost its own sales — the drug maker has unveiled a new ADHD-related support resource available through the online networking medium Twitter.

Read More at BNET PHARMA….

Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.

No comments: